Skip to main content

Table 1 Recent targeted therapy study results in melanoma

From: Novel melanoma therapy

Study Agent(s) Phase of study Median PFS (months) OS ORR (%)
[4] Dabrafenib + trametinib II 9.4 79 % at 1 year 76
Dabrafenib 5.8 70 % at 1 year 54
[16]
[17]
Dabrafenib + trametinib III 11.0 25.1 months 67
Dabrafenib 8.8 18.7 months 51
[18] Dabrafenib + trametinib III 11.4 72 % at 1 year 64
Vemurafenib 7.3 65 % at 1 year 51
[19]
[20]
Cobimetinib + vemurafenib I/II Vemurafenib refractory: 2.8 8.4 months 15
Vemurafenib naïve: 13.7 28.5 months 87
[21]
[22]
Cobimetinib + vemurafenib III 12.3 81 % at 9 months 70
Vemurafenib 7.3 73 % at 9 months 50
[23] Encorafenib + binimetinib I/II 11.3 NA 74.5
[24] Binimetinib III NA NA 15
DTIC 7